BG102125A - Нови доластатинови производни, тяхното получаванеи приложение - Google Patents

Нови доластатинови производни, тяхното получаванеи приложение

Info

Publication number
BG102125A
BG102125A BG102125A BG10212597A BG102125A BG 102125 A BG102125 A BG 102125A BG 102125 A BG102125 A BG 102125A BG 10212597 A BG10212597 A BG 10212597A BG 102125 A BG102125 A BG 102125A
Authority
BG
Bulgaria
Prior art keywords
dolastine
derivatives
preparation
new
application
Prior art date
Application number
BG102125A
Other languages
English (en)
Inventor
Andreas Haupt
Franz Emling
Cynthia Romerdahl
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of BG102125A publication Critical patent/BG102125A/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Доластатиновите производни имат антинеопластичен ефект. Те са с формула R1R2N-CHX-A-B-D-E-(F)t-K 1 2, в която R1, R2, A, B, D, E, F, K, X и t имат значенията, посочени в описанието. Изобретението се отнася и до получаването на тези съединения.
BG102125A 1995-06-07 1997-12-18 Нови доластатинови производни, тяхното получаванеи приложение BG102125A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/472,453 US5831002A (en) 1992-05-20 1995-06-07 Antitumor peptides
PCT/EP1996/002392 WO1996040751A1 (en) 1995-06-07 1996-06-03 Novel dolastatin derivatives, their preparation and use

Publications (1)

Publication Number Publication Date
BG102125A true BG102125A (bg) 1998-09-30

Family

ID=23875567

Family Applications (2)

Application Number Title Priority Date Filing Date
BG102125A BG102125A (bg) 1995-06-07 1997-12-18 Нови доластатинови производни, тяхното получаванеи приложение
BG102152A BG102152A (bg) 1995-06-07 1997-12-29 Нови доластатинови производни, тяхното получаванеи приложение

Family Applications After (1)

Application Number Title Priority Date Filing Date
BG102152A BG102152A (bg) 1995-06-07 1997-12-29 Нови доластатинови производни, тяхното получаванеи приложение

Country Status (33)

Country Link
US (1) US5831002A (bg)
EP (2) EP0871656B1 (bg)
JP (2) JP3957751B2 (bg)
KR (2) KR100437985B1 (bg)
CN (2) CN1182153C (bg)
AR (2) AR003136A1 (bg)
AT (2) ATE224910T1 (bg)
AU (2) AU725164B2 (bg)
BG (2) BG102125A (bg)
BR (2) BR9609424A (bg)
CA (2) CA2219818C (bg)
CO (2) CO4700527A1 (bg)
CZ (2) CZ293682B6 (bg)
DE (2) DE69623472T2 (bg)
DK (2) DK0871656T3 (bg)
ES (2) ES2186783T3 (bg)
HR (2) HRP960277A2 (bg)
HU (2) HU228073B1 (bg)
IL (2) IL122215A (bg)
MX (2) MX9709146A (bg)
MY (2) MY119042A (bg)
NO (2) NO318384B1 (bg)
NZ (2) NZ310444A (bg)
PL (2) PL185762B1 (bg)
PT (2) PT871656E (bg)
RO (2) RO118953B1 (bg)
SI (2) SI0832104T1 (bg)
SK (1) SK282466B6 (bg)
TR (2) TR199701545T1 (bg)
TW (2) TW508357B (bg)
UA (2) UA46776C2 (bg)
WO (2) WO1996040751A1 (bg)
ZA (2) ZA964710B (bg)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
EP1159273A1 (en) 1999-03-02 2001-12-05 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cathepsin s
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CA2445591A1 (en) 2001-04-27 2002-11-07 The Procter & Gamble Company Nitrogen heterocyclic compounds and compositions for controlling biofilms
WO2003051835A2 (en) * 2001-12-18 2003-06-26 Proteologics, Inc. Methods and compositions for the inhibition of viral release
EP1531846A4 (en) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv CONJUGATES OF LIGAND, LINK AND CYTOTOXIC AGENS, AND RELATED COMPOSITIONS AND USE PROCESSES
EP1781310B1 (en) 2004-08-02 2015-10-14 Ramot at Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Birドメイン結合化合物
US20080292616A1 (en) * 2005-08-19 2008-11-27 Government Of The United Of America, Represented By The Secretary, Department Of Health And.... Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same
WO2007043048A2 (en) * 2005-10-11 2007-04-19 Ramot At Tel Aviv University Ltd. Self-assembled fmoc-ff hydrogels
EP2024362A4 (en) 2006-05-16 2012-01-25 Pharmascience Inc IAP BIR DOMAIN BINDING COMPOUNDS
CL2007002166A1 (es) * 2006-07-24 2008-01-25 Tetralogic Pharm Corp Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
WO2008127560A1 (en) * 2007-04-12 2008-10-23 Scinopharm Taiwan Ltd. Process for making galantamine
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
JP2014502620A (ja) 2010-12-30 2014-02-03 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状c型肝炎セリンプロテアーゼ阻害剤
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EP3470413A3 (en) 2011-05-27 2019-08-07 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
JPWO2023033129A1 (bg) 2021-09-03 2023-03-09

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
EP0598129B1 (en) * 1991-08-09 2000-03-22 Teikoku Hormone Mfg. Co., Ltd. Novel tetrapeptide derivative
CZ292612B6 (cs) * 1992-05-20 2003-11-12 Abbott Gmbh & Co. Kg Peptid s protirakovinnou aktivitou, jeho použití a farmaceutický prostředek s obsahem takového peptidu
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters

Also Published As

Publication number Publication date
BR9609423A (pt) 1999-06-29
MY119042A (en) 2005-03-31
WO1996040752A1 (en) 1996-12-19
MX9709146A (es) 1998-03-31
TW508357B (en) 2002-11-01
UA46775C2 (uk) 2002-06-17
CA2219819A1 (en) 1996-12-19
SK282466B6 (sk) 2002-02-05
NO318384B1 (no) 2005-03-14
DE69623992T2 (de) 2003-05-22
HU228073B1 (hu) 2012-09-28
IL122215A (en) 2001-08-26
DE69623472D1 (de) 2002-10-10
PL185763B1 (pl) 2003-07-31
BR9609424A (pt) 2000-03-28
AU6124296A (en) 1996-12-30
HRP960257A2 (en) 1998-02-28
US5831002A (en) 1998-11-03
AR003427A1 (es) 1998-08-05
HU228071B1 (hu) 2012-09-28
HRP960277A2 (en) 1997-10-31
AU725164B2 (en) 2000-10-05
ZA964710B (en) 1997-12-08
EP0871656A1 (en) 1998-10-21
SI0871656T1 (en) 2003-08-31
AU725170B2 (en) 2000-10-05
ES2188759T3 (es) 2003-07-01
DE69623472T2 (de) 2003-08-21
CA2219818C (en) 2008-05-20
RO119783B1 (ro) 2005-03-30
CZ376597A3 (cs) 1998-06-17
NZ310444A (en) 1999-11-29
EP0871656B1 (en) 2002-09-25
MX9709147A (es) 1998-03-31
PL323723A1 (en) 1998-04-14
JP4221062B2 (ja) 2009-02-12
AU6124196A (en) 1996-12-30
HUP9801817A2 (hu) 1998-11-30
ZA964711B (en) 1997-12-08
CO4700527A1 (es) 1998-12-29
EP0832104A1 (en) 1998-04-01
CZ293683B6 (cs) 2004-07-14
PL323726A1 (en) 1998-04-14
CZ293682B6 (cs) 2004-07-14
CA2219818A1 (en) 1996-12-19
NO975710D0 (no) 1997-12-05
KR100437986B1 (ko) 2004-09-18
AR003136A1 (es) 1998-07-08
ATE223431T1 (de) 2002-09-15
TW424096B (en) 2001-03-01
CN1182154C (zh) 2004-12-29
DK0871656T3 (da) 2003-01-27
CN1182153C (zh) 2004-12-29
RO118953B1 (ro) 2004-01-30
JPH11504652A (ja) 1999-04-27
PL185762B1 (pl) 2003-07-31
NZ310443A (en) 1999-10-28
KR19990022583A (ko) 1999-03-25
CO4700526A1 (es) 1998-12-29
IL122216A (en) 2002-02-10
JPH11504653A (ja) 1999-04-27
SI0832104T1 (en) 2003-08-31
CA2219819C (en) 2008-05-20
DE69623992D1 (de) 2002-10-31
IL122215A0 (en) 1998-04-05
CZ376397A3 (cs) 1998-06-17
IL122216A0 (en) 1998-04-05
WO1996040751A1 (en) 1996-12-19
CN1187198A (zh) 1998-07-08
DK0832104T3 (da) 2003-01-06
TR199701545T1 (xx) 1998-04-21
KR19990022582A (ko) 1999-03-25
NO317670B1 (no) 2004-11-29
PT871656E (pt) 2002-12-31
NO975710L (no) 1998-02-02
HUP9801910A3 (en) 1999-06-28
JP3957751B2 (ja) 2007-08-15
BG102152A (bg) 1998-09-30
ATE224910T1 (de) 2002-10-15
KR100437985B1 (ko) 2004-09-18
EP0832104B1 (en) 2002-09-04
SK165397A3 (en) 1998-10-07
PT832104E (pt) 2002-12-31
MY124487A (en) 2006-06-30
UA46776C2 (uk) 2002-06-17
HUP9801817A3 (en) 1999-06-28
CN1187199A (zh) 1998-07-08
TR199701544T1 (xx) 1998-03-21
NO975711L (no) 1998-01-30
NO975711D0 (no) 1997-12-05
HUP9801910A2 (hu) 1999-01-28
ES2186783T3 (es) 2003-05-16

Similar Documents

Publication Publication Date Title
BG102125A (bg) Нови доластатинови производни, тяхното получаванеи приложение
HK1010196A1 (en) Novel 2,3-dioxo-1,2,3,4-tetrahdro-quinoyxalinyl derivatives.
AU1642095A (en) 3,5-disubstituted tetrahydrofuran-2-ones
AU1416195A (en) Substituted 1,2,3,4-tetrahydro-5-nitro pyrimidines
GEP20012416B (en) Benzopyran Derivatives Having Leukotriene-Antagonistic Action
HK1032785A1 (en) Novel 3,6-hemiketals from the class of 9a-azalides
AU6123196A (en) N-aryl-1,2,4-triazolin-5-ones
ZA945238B (en) 1,5 Benzodiazepine derivatives.
ZA962753B (en) 1,3-Dihydro-2H-imidazol-2-one derivatives.
MX9706744A (es) Proceso novedosos para preparar derivados de 2,3-dihidro-benzofuranol.
AU4361696A (en) New uses of indolo-{2,3b}-quinoxalines
AU7716691A (en) Steam iron, particularly of the drop type
ZA965465B (en) 2,4,5-Trisubstituted phenylketoenois
HU908313D0 (en) New 15-nitro-2betha, 3betha-dihydro- and 15-nitro-2betha, 3 betha,6,7-tetrahydro-tabersonine derivatives
MY114327A (en) Novel peptides, the preparation and use thereof
EP0654995A1 (en) 4-OXA-1-AZABICYCLO (3,2,0) HEPTAN-7-ONE DERIVATIVES AS AN ANTITUARY ACTIVE SUBSTANCES.
AU2137095A (en) Heterocyclyl-1,3,4-thiadiazolyloxyacetamides
ZA966542B (en) Process for the preparation of 3,3,5-trichloroglutarimide.
AU1655695A (en) 8-amino-pyrido (1,2,3-d,e)(1,3,4) benzoxadiazine derivatives
AU1325095A (en) Novel 3-(substituted methyl)-4-oxa-1-azabicyclo{3.2.0}heptan-7-one derivatives useful as antitumor agents
AU1955492A (en) 3,4-dehydropiperidine derivatives
ZA967322B (en) Novel 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives.
AU7098391A (en) New azaspyro(4.5)decane-7,9-dione derivatives
ZA983781B (en) Process for the preparation of 1,1,1,3,3-pentachlorobutane.
MX9700585A (es) Derivados de n-alcoxi-amidina y su empleo como agentes pesticidas.